NASDAQ OMX

Taconic Biosciences Secures CRISPR License From ERS Genomics

30.5.2017 18:34 | NASDAQ OMX

Dela

HUDSON, N.Y., May 30, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced it has signed a license agreement with ERS Genomics ("ERS") to utilize the company's CRISPR-Cas9 technology to generate unique murine models.

Under the agreement, Taconic receives a worldwide non-exclusive license to the CRISPR-Cas9 patents often referred to as the "UC Berkeley patent." ERS Genomics founder, Emmanuelle Charpentier, is a co-inventor of the CRISPR-Cas9 technology. This agreement with ERS complements Taconic's CRISPR service platform, adding to its existing license with the Broad Institute. Holding licenses with both groups provides Taconic access for use in all cell types as well as for use in both mouse and rat species, a rare distinction within the animal model field.

"There is no doubt that CRISPR-Cas9 has revolutionized gene editing and thus drug discovery. Adding the ERS technology to Taconic's existing CRISPR platform allows the company to stand out among competitors by offering a fully-licensed, comprehensive CRISPR platform," shared Dr. John Couse, Taconic Biosciences' director of genetically modified model design. 

"We are very pleased to add Taconic to our list of licensees as it furthers our goal of making this technology more broadly accessible and Taconic is certainly a globally recognized leader in the animal model field," added Eric Rhodes, chief executive officer of ERS.  

Taconic is a fully-licensed provider of rodent model generation services and has twenty years of model design experience. The company provides gene inactivation, gene mutation or replacement, transgene expression, RNAi, and gene editing via CRISPR-Cas9, pronuclear injection, and homologous recombination technologies to ensure that the right tools are leveraged for each specific customer project. Taconic's unique capability of providing a seamless transition from model design to breeding and colony management, offers customers a complete solution. These scientific services include acquiring or generating, importing, licensing, breeding, testing, preparing, and distributing genetically engineered models to any location worldwide.

To learn more about Taconic's custom model generation, please call 1-888-TACONIC (888-822-6642) in the US, or +45 70 23 04 05 in Europe, or email info@taconic.com.

About Taconic Biosciences, Inc.

Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide.  Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.

Media Contact:
Kelly Owen Grover
Director of Marketing Communications
(518) 697-3824
kelly.grover@taconic.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Taconic Biosciences via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

LifeSci Advisors' Board Placement Initiative Announces Ninth Board Placement23.6.2017 17:52Pressmeddelande

NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- LifeSci Advisors, a leading life sciences-focused investor relations consultancy, announced today the ninth placement of a female executive to a life sciences company board as part of their Board Placement Initiative (BPI), a program launched a year ago with the goal to connect female executives in the life sciences industry with companies looking for board candidates. LifeSci is pleased to share news of the appointment of Jean M. Franchi to the Board of Directors of Biophytis, a biotech company listed on Euronext Paris (ALBPS) focused on drugs that target diseases of aging, with drug candidates in clinical development for dry AMD and Sarcopenia. "I'm honored to join the Biophytis board, and look forward to helping the company achieve a more global presence as it advances its portfolio of innovative therapies addressing unmet needs associated with aging," said Ms. Franchi. "I want to extend my kind thanks to LifeSci

Fentress Architects Announces its Annual Student Global Challenge23.6.2017 09:00Pressmeddelande

6th edition invites students to re-envision the terminal building in the year 2075 Denver, Colorado, June 23, 2017 (GLOBE NEWSWIRE) -- Fentress Architects, based in Denver, Colorado, announces the 2017 Fentress Global Challenge, an international design competition for young and student architects. As in years past, the theme, consistent with the firm's expertise in airport design and aviation, is envisioning an airport of the future.  Participants are encouraged to re-envision the terminal building in the year 2075 using one of 10 existing international airports, taking into consideration local context, technological trends, and project feasibility and passenger experience. This is the sixth year that Fentress Architects has sponsored and administered the award, which brings a First Prize of $15,000 and a summer internship at Fentress' Denver office; four additional winners will receive smaller cash awards.

Oxford Immunotec Announces National Reimbursement for the T-SPOT®.TB Test in France22.6.2017 22:50Pressmeddelande

OXFORD, United Kingdom and MARLBOROUGH, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced a decision from the French Ministry of Health and Social Affairs to reimburse interferon gamma release assays, or IGRAs, for latent TB screening in at risk patient populations. Upon implementation of the new reimbursement codes, which is expected in the next 21 days, the French Ministry of Health and Social Affairs will provide reimbursement for the T-SPOT. TB  test at a rate of approximately 60 Euros per test. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-r

Standard Lithium Raises $7.4 Million in Oversubscribed Financing22.6.2017 21:49Pressmeddelande

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 22, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLL) (FRA:S5L) is pleased to announce that it has completed the private placement of 9,894,785 common shares at a price of $0.75 per share for gross proceeds of $7,421,089.  Interest in the placement far exceeded the expectations of the Company, and the additional amount raised provides the Company with the capital needed to advance its current projects and pursue strategic acquisitions in the lithium sector. "We are extremely pleased with the interest received in this placement, and completion represents a significant milestone for the Company," commented Anthony Alvaro, a director of the Company.  "The strong demand speaks to the growing confidence in our team, projects and futur

IAGC: Plankton Study Speculative and Needs Better Data22.6.2017 16:08Pressmeddelande

Houston, TX, US, June 22, 2017 (GLOBE NEWSWIRE) -- The International Association of Geophysical Contractors (IAGC) released the following statement regarding the publishing of research on the interaction of seismic surveys and zooplankton in Nature: Ecology and Evolution. The IAGC President, Nikki Martin issued the following statement: "While we found the study interesting, we are also troubled by the small sample sizes, the large day-to-day variability in both the baseline and experimental data, and the large number of speculative conclusions that appear inconsistent with the data collected over a two-day period.  Both statistically and methodologically, this project falls short of what would be needed to provide a convincing case for adverse effects from geophysical survey operations.  "Although the initial report is peer-reviewed, it has not been widely accepted by the expert scientific community.  We look forward to discussing this topic further with

Minerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With Schizophrenia22.6.2017 14:30Pressmeddelande

New formulation observed to improve safety margin while offering bioequivalent exposure to prior formulation Company to proceed with initiation of Phase 3 trial on schedule in second half of 2017 CMC scale-up work for NDA preparation initiated WALTHAM, Mass., June 22, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the successful completion of a bridging trial to select an improved, gastric-resistant (GR) formulation of MIN-101. The Company plans to use the selected formulation in its upcoming Phase 3 clinical trial, which remains on schedule for initiation in the second half of 2017, as well as for the potential future submission of a New Drug Application (NDA). 

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum